Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2020
2019
2018
Profitability Metrics
Gross Margin
88.33%
Operating Margin
20.32%
Net Margin
66.07%
Efficiency Metrics
Revenue per Expense Ratio
1.47
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
87.70%
Income Tax Rate
0.00%
EPS
1.5000000000
Balance Sheet Analysis
Current Ratio
1,229.2
Cash Ratio
9.27
Working Capital
$140.36M
Debt to Equity
0.37
Debt to Assets
27.13%
Equity Ratio
72.68%
Cash Flow Analysis
Operating Cash Flow Ratio
65.04%
Free Cash Flow Ratio
65.04%
CapEx to Revenue
0.00%
Dividends Paid
$8.59M
Stock Buybacks
No buybacks
Total Shareholder Returns
$8.59M
Cash Position Change
-100.00%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 47.49%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
200.93%
Net Income
165.43%
EPS
165.50%
Operating Income
122.41%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
2.53%
Operating Cash Flow
307.94%
Free Cash Flow
307.94%
Balance Sheet Health
Assets
-5.08%
Debt
-15.61%
Book Value per Share
-0.39%
Inventory
0.00%
Shareholder Returns
Dividends per Share
47.49%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
1,113.66%
5Y Revenue/Share
422.95%
3Y Dividend/Share
60.72%
5Y Dividend/Share
-24.55%